The DOI matches its Crossref record.
Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimerʼs disease
Abstract
Using two-site enzyme immunoassays (EIAs), we measured the levels of neurotrophins, nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) simultaneously in three brain regions (motor cortex, dentate gyrus and entorhinal cortex) of patients with Alzheimer's disease (AD) and control individuals. Significant differences between the neurotrophin levels of these two groups were found in the different brain regions depending on the neurotrophin. The NGF level in the dentate gyrus of AD patients was higher, whereas the BDNF level in the entorhinal cortex and the NT-3 level in the motor cortex were lower than the corresponding control levels. These results indicate that protein levels of individual neurotrophins in different brain regions are affected differently by AD, and such differential changes may contribute to the complex pathology of AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A reduced level of BDNF has been found in patients affected by neurodegenerative diseases such as Parkinson’s, Huntington’s and Alzheimer’s disease as well as in mild cognitive impairment, the latter being a prodromal stage of AD, characterized by a slight decline of cognitive abilities including memory, thinking and judging skills [242,243,244,245].”
From Neurotrophic Factor BDNF, Physiological Functions and Therapeutic Potential in Depression, Neurodegeneration and Brain Cancer (2020) · cites this paper as [244]
In the citing paper
“Furthermore, amounts of BDNF protein are reduced in the entorhinal cortex and hippocampus in Alzheimer’s disease7–9.”
From Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease (2009) · cites this paper as [7]
In the citing paper
“Notably, the concentrations of BDNF decline in the entorhinal cortex and hippocampus in Alzheimer’s disease7–9”
From Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease (2009) · cites this paper as [7]
Citations
Cited by
Sorted by citations
Items 201–226 of 226
Current approaches and future directions of gene therapy in Alzheimer’s disease
Stepanichev, M. Y. (2011) · Neurochemical Journal · doi:10.1134/s181971241103010x · Cited by 4
Growth Factors in Alzheimer’s Disease
Nagahara, A. H., & Tuszynski, M. H. (2007) · Springer eBooks · doi:10.1007/978-0-387-35135-3_15 · Cited by 3
Vasilopoulou, F., Companys‐Alemany, J., Canudas, A.-M., Palomera‐Ávalos, V., Ortuño‐Sahagún, D., Pallàs, M., & Griñán‐Ferré, C. (2021) · Preprints.org · doi:10.20944/preprints202101.0162.v1 · Cited by 2
“Moreover, it has been reported a slight reduction of NT3 in the cortex of AD patients [16] as well decreased levels of NGF in the hippocampus of several older rodent models, including AD models [17].”
BackgroundMasullo, M., Agbangla, N. F., & Arcone, R. (2025) · RIVISTA DI STUDI SULLA SOSTENIBILITA · doi:10.3280/riss2025oa19843 · Cited by 3
Focused ultrasound: Innovation in use for neurologic conditions
Siyanaki, M. R. H., Pierre, K., Felisma, P., Mampre, D. M., Stein, A., Fusco, A. F., Reddy, R., Chandra, V., & Lucke-Wold, B. P. (2023) · Trauma and Emergency Medicine · doi:10.46439/trauma.1.001 · Cited by 2
Cellular and molecular mechanisms of Alzheimer’s disease inflammation
Peery, H. E., Strohmeyer, R., & Rogers, J. (2001) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8350-4_1 · Cited by 2
The cholinotrophic system in Down syndrome
Mufson, E. J., & Perez, S. E. (2025) · Handbook of clinical neurology · doi:10.1016/b978-0-443-19088-9.00017-2 · Cited by 1
Growth factors and their receptors
Lazaldin, M. A. M., Lambuk, L., Ahmad, S., & Mohamud, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18677-6.00005-1 · Cited by 1
Fa, Z., Chen, J., Li, Y., Ye, J., & Wang, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316993 · Cited by 1
Vasilipoulou, F., Companys‐Alemany, J., Canudas, A.-M., Palomera‐Ávalos, V., Ortuño‐Sahagún, D., Pallàs, M., & Griñán‐Ferré, C. (2020) · Preprints.org · doi:10.20944/preprints202011.0336.v1
“Also, a slight reduction of NT3 in the cortex of AD patients have been described [13].”
BackgroundRole of Huntington’s Disease Protein in Post-Transcriptional Gene Regulatory Pathways
Brady, P., & Tanese, N. (2012) · InTech eBooks · doi:10.5772/30855
Effect of Exercise Training for the Chronic Hemodialysis Patients
西地, 令., & 鷲尾, 昌. (2013) · Institutional Repositories DataBase (IRDB)
Stimulating Neuroprotective and Regenerative Mechanisms in Alzheimer Disease
Lilja, A. M. (2013) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.8515
“In AD, levels of BDNF are decreased in the entorhinal cortex and the hippocampus (Connor et al., 1997; Hock et al., 2000; Narisawa-Saito et al., 1996).”
BackgroundOne more view of neurotrophin-netrotrasmitter signaling in neurons: BDNF-AMPAR crosstalk
Chaldakov, G. N. (2008) · Biomedical Reviews · doi:10.14748/bmr.v19.58
“calization of BDNF and TrkB receptor to glutamate synapses makes this system intriguing as a dynamic, activity-dependent regulator of excitatory transmission that is implicated in the mechanisms of memory storage and mood control (10-12) as well as neuropsychiatric diseases (13-15).”
BackgroundModulation of Alzheimer's Disease Pathology and Neuroplasticity by Environmental Factors
Hu, Y. (2012) · Figshare
Small Molecule Activators of the TRK Receptors for Neuroprotection
Webster, N. J., Krajewski, S., & Pirrung, M. C. (2011) · doi:10.21236/ada555936
Neuroprotection induced by neurotrophic factors
Réus, G. Z., Manosso, L. M., Botelho, M. E. M., Arent, C. O., Pedro, L. C., & Quevedo, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23763-8.00063-4
Nerve Growth Factor and Brain-Derived Neurotrophic Factor Gene Therapy for Alzheimer’s Disease
Tuszynski, M. H. (2025) · Springer eBooks · doi:10.1007/978-3-031-89307-0_4
NEUROTROPHIC FACTORS IN ALZHEIMER'S DISEASE
Blesch, A., & Tuszynski, M. H. (2008) · Elsevier eBooks · doi:10.1016/b978-012373994-0.50010-5
Optimizing cancer outcomes: Exercise prescription in integrative oncology
Encabo, P. G., Patel, D. I., & Dieli-Conwright, C. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30194-0.00058-8
BDNF–amyloid-β Axis in Alzheimer’s disease: molecular mechanisms and therapeutic perspectives
Liu, F., Huang, Y., Wang, A., Peiyan, L., Wu, H., & Fan, H. (2026) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2026.1884003
Karsuntseva, E. K., Voronova, A. D., Stepanova, O. V., Степаненко, А. А., Shishkina, V. S., Fursa, G. A., Chadin, A. V., Reshetov, I. V., Gurina, O. I., & Chekhonin, V. P. (2026) · Cells · doi:10.3390/cells15181706
“Variable NT-3 dynamics have been demonstrated both in the brains of patients [46] and in experimental AD models [47].”
Beating Around the “Wrong” Bush?
Watve, M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4409-1_13
Metadata
- Authors
- Narisawa-Saito, M., Wakabayashi, K., Tsuji, S., Takahashi, H., & Nawa, H.
- Affiliations
- Brain Research Institute, Niigata University (JP)
- Venue
- NeuroReport
- Published
- 1996-11
- Volume
- 7
- Issue
- 18
- Pages
- 2925-2928
- ISSN
- 0959-4965 (ISSN-L)
- OpenAlex
- W2055746351
- Cited by
- 226
- References
- 0
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 6 · 2023: 6 · 2022: 7 · 2021: 10 · 2020: 11 · 2019: 5 · 2018: 6 · 2017: 6 · 2016: 12 · 2015: 6 · 2014: 9 · 2013: 15 · 2012: 10
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuroreport (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, neurotrophins, nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3, regional brain differences, dentate gyrus, entorhinal cortex, motor cortex
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Animals, Brain Chemistry, Humans, Immunoenzyme Techniques, Middle Aged, Nerve Growth Factors, Postmortem Changes, Rats, Sprague-Dawley, Entorhinal Cortex, Dentate Gyrus, Brain-Derived Neurotrophic Factor, Neurotrophin 3, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
